Lilly, B-Ingelheim deal adds to buzz in Indian diabetes market

Global partners in the diabetes segment, Boehringer Ingelheim and Lilly, have entered into an India-specific co-promotion deal for a basket of diabetes compounds in both late-stage development or on the market, adding to the string of such alliances in the country.

Global partners in the diabetes segment, Boehringer Ingelheim and Lilly, have entered into an India-specific co-promotion deal for a basket of diabetes compounds in both late-stage development or on the market, adding to the string of such alliances in the country.

The collaboration includes Boehringer Ingelheim's oral antidiabetic agent linagliptin, which has yet to be approved for marketing in India, and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category